The Filing Desk

Biodesix vs Cryo Cell International

Biodesix BDSX · Cryo Cell International CCEL · Health Care Services

Biodesix reported revenue of $88 million in fiscal 2025, 2.8 times Cryo Cell International's $32 million in fiscal 2025. Biodesix's revenue grew 24.1% in its latest year, and Cryo Cell International's fell 1.3%. Biodesix had an operating margin of -31.5%, against 1.5% at Cryo Cell International. Free cash flow was −$24 million at Biodesix and $5 million at Cryo Cell International. Their fiscal years end in different months (December 31 and November 30), so the periods don't line up exactly.

Side by side

BiodesixCryo Cell International
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Nov 30, 2025
Revenue$88M$32M
Revenue growth24.1%−1.3%
Revenue growth a year, last 5 years14.2%0.3%
Gross margin—76.6%
Operating margin−31.5%1.5%
Net margin−39.9%−7.7%
Free cash flow−$24M$5M
Free cash flow margin−26.6%16.6%
Return on capital−69.7%—
Net debt to EBITDA—3.5x
Dividends and buybacks$0M$3M
Change in diluted share count16.7%−1.8%
Last close$8.30$4.15
P/E at the last close——
Insider trades, last 12 monthsbought $3.1 million, sold $104,401—
Piotroski F-score3 of 86 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
BiodesixCryo Cell International
Operating margin
Percent of revenue
BiodesixCryo Cell International
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BiodesixCryo Cell International

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Biodesix and Cryo Cell International pages.